Cannabis for Glaucoma: Lowers IOP But Not a Standalone Treatment

Cannabis (THC) lowers intraocular pressure (IOP) by 20–30% for 3–4 hours via CB1 receptors in the ciliary body. However, **it is not a recommended monotherapy for glaucoma.**

Why Cannabis Falls Short

LimitationImpact
Short durationRequires dosing every 3–4 hours (6–8×/day) for continuous IOP control—impractical, impairing.
Systemic side effectsTachycardia, hypotension, dizziness, cognitive impairment, psychoactivity → falls, driving risk.
ToleranceCB1 downregulation → diminished IOP effect within weeks; requires escalating doses.
No neuroprotection evidenceGlaucoma is neurodegenerative; IOP lowering alone may not halt progression if perfusion compromised.
Delivery challengesSmoking harms lungs; oral erratic absorption; topical THC eye drops not commercially available (poor corneal penetration).

Current Standard of Care

  • First-line: Prostaglandin analogs (latanoprost, travoprost) — once nightly, 25–33% IOP reduction, minimal systemic effects.
  • Add-ons: β-blockers, α₂-agonists, CAIs, Rho kinase inhibitors.
  • Laser: SLT (selective laser trabeculoplasty) — first-line alternative.
  • Surgery: MIGS, trabeculectomy, tube shunt for refractory cases.

When Cannabis Might Be Considered

  • Adjunct in refractory cases *under ophthalmologist supervision* where standard therapies failed/intolerable.
  • Symptom management (pain, nausea, anxiety) in advanced glaucoma patients.
  • Research settings: CB2 agonists, synthetic cannabinoids with longer duration, no psychoactivity.

Key Message

Do not self-treat glaucoma with cannabis. It risks vision loss from inadequate 24-hour IOP control and systemic impairment. See an ophthalmologist for evidence-based therapy.

Prescription Medications - Related Articles